| Literature DB >> 28928444 |
Jos P H Smits1, Hanna Niehues1, Gijs Rikken1, Ivonne M J J van Vlijmen-Willems1, Guillaume W H J F van de Zande2, Patrick L J M Zeeuwen1, Joost Schalkwijk1, Ellen H van den Bogaard3.
Abstract
The strong societal urge to reduce the use of experimental animals, and the biological differences between rodent and human skin, have led to the development of alternative models for healthy and diseased human skin. However, the limited availability of primary keratinocytes to generate such models hampers large-scale implementation of skin models in biomedical, toxicological, and pharmaceutical research. Immortalized cell lines may overcome these issues, however, few immortalized human keratinocyte cell lines are available and most do not form a fully stratified epithelium. In this study we compared two immortalized keratinocyte cell lines (N/TERT1, N/TERT2G) to human primary keratinocytes based on epidermal differentiation, response to inflammatory mediators, and the development of normal and inflammatory human epidermal equivalents (HEEs). Stratum corneum permeability, epidermal morphology, and expression of epidermal differentiation and host defence genes and proteins in N/TERT-HEE cultures was similar to that of primary human keratinocytes. We successfully generated N/TERT-HEEs with psoriasis or atopic dermatitis features and validated these models for drug-screening purposes. We conclude that the N/TERT keratinocyte cell lines are useful substitutes for primary human keratinocytes thereby providing a biologically relevant, unlimited cell source for in vitro studies on epidermal biology, inflammatory skin disease pathogenesis and therapeutics.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28928444 PMCID: PMC5605545 DOI: 10.1038/s41598-017-12041-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Studies using in vitro 3D reconstructed skin generated from N/TERT keratinocytes.
| 3D skin model | Dermal matrix | F | Epidermal morphology | Field of study | Reference |
|---|---|---|---|---|---|
| HSE | Collagen type I | Y | Stratified epidermis, sc present | Cell line development | Dickson |
| HSE | Collagen type I | Y | Stratified epidermis, sc present | Cell line development | Rheinwald |
| HSE | DED | Y | Stratified epidermis, sc present | Epidermal biology | Wan |
| HSE | DED | Y | Stratified epidermis, sc present | Skin barrier | Man |
| HSE | Collagen type I | Y | Stratified epidermis, sc present | Epidermal biology | Dabelsteen |
| HEE | None | N | Stratified epidermis, sc present | UV radiation, DNA damage | Bertrand-Vallery |
| HSE | Collagen type I | N | Stratified epidermis, sc present | Human papillomavirus | Lazic |
| HEE | None | N | Stratified epidermis, sc present | Epidermal biology | Robertson |
| HSE | Collagen type I | Y | Stratified epidermis, sc present | Skin barrier | Van Drongelen |
| HSE | Collagen type I | Y | Multilayer of cells, sc lacking | UV radiation, DNA damage | Harrison |
| HSE | Collagen type I | Y | Multilayer of cells, sc present | Ionizing radiation, DNA damage | Acheva |
| HSE | Collagen type I | Y | Stratified epidermis, sc present | Skin barrier | Van Drongelen |
| HEE | None | N | Stratified epidermis, sc present | Epidermal biology | Van Drongelen |
| HEE | None | N | Stratified epidermis, sc present | Skin sensitization | Alloul-Ramdhani |
| HSE | Matriderm | Y | Stratified epidermis, sc present | Epidermal biology | Reijnders |
| HSE | Collagen type I | Y | Stratified epidermis, sc present | Ionizing radiation, inflammation | Acheva |
$Initial paper describing the N/TERT cell line development; HSE: human skin equivalent; HEE: human epidermal equivalent; DED: de-epidermized dermis; F: Fibroblasts present Yes/No; UV: ultraviolet; sc: stratum corneum.
Figure 1N/TERT keratinocytes express terminal differentiation genes. mRNA expression of epidermal differentiation genes by N/TERT keratinocyte monolayer cultures (N = 3 for N/TERT 1 and N/TERT2G) were compared to primary keratinocytes (N = 6 donors). Bars represent mean ± SEM. *p < 0.05 relative to primary keratinocyte at the same time point.
Figure 2N/TERT1 keratinocytes are suitable for culture in HEE models. (A) Haematoxylin Eosin (HE) staining of N/TERT1 keratinocytes in the HEE model system while developing from day 2 to day 10 of air exposure. (B) Epidermal barrier properties of the HEE constructs by biotin penetration (red) and Lucifer yellow penetration (green). Scale bar = 100 µm.
Figure 3N/TERT keratinocytes and primary keratinocytes respond similar to pro-inflammatory cytokine stimulation in conventional monolayer cultures. (A) Terminal differentiation genes and (B) psoriasis marker mRNA expression of monolayer N/TERT keratinocytes and primary keratinocytes after stimulation with Th1 cytokines (IL-1α, TNFα, and IFNγ). (C) Terminal differentiation genes and (D) AD marker mRNA expression of monolayer N/TERT keratinocytes and primary keratinocytes after stimulation with Th2 cytokines (IL-4 and IL-13). Bars represent mean ± SEM. *p < 0.05 **p < 0.01 ***p < 0.001 relative to primary keratinocytes.
Figure 4N/TERT1 keratinocytes are suitable to generate a psoriasis-like HEE (PS-HEE) disease model. (A,B) N/TERT HEEs were harvested for mRNA expression analysis and (C) morphological analysis after stimulation with Th1 cytokines (TNFα, IL-6, and IL-1α) and rescued by addition of all trans retinoic acid (ATRA). (D,E) N/TERT HEEs were harvested for mRNA expression analysis and (F,G) morphological analysis after stimulation with Th17 cytokines (IL-17 and IL-22) and rescued by addition of all trans retinoic acid (ATRA). Images are representative of N = 3 N/TERT HEE experiments. Bars represent mean ± SEM. *p < 0.001 **p < 0.01 relative to control unstimulated keratinocytes. Scale bar = 100 µm.
Figure 5N/TERT1 keratinocytes can be used to generate a atopic dermatitis-like HEE (AD-HEE) disease model. (A) mRNA expression of N/TERT1 HEEs after coal tar stimulation. Activation of the aryl hydrocarbon receptor (AHR) is measured via the induction of the AHR target gene, CYP1A1. (B) N/TERT HEEs were harvested for mRNA and (C) morphological analysis after stimulation with Th2 cytokines (IL-4 and IL-13) and rescued by addition of coal tar extract. (D) Protein expression was visualised by immunohistochemistry. Bars represent mean ± SEM. *p < 0.05 **p < 0.01 ***p < 0.001. Scale bar = 100 µm.
Primer sequences of all primers.
| Gene | Name | Forward primer (5′–3′) | Reverse primer (5′–3′) |
|
|---|---|---|---|---|
|
| Filaggrin | acttcactgagtttcttctgatggtatt | tccagacttgagggtctttttctg | 1.89 |
|
| Loricrin | aggttaagacatgaaggatttgcaa | ggcaccgatgggcttagag | 2.08 |
|
| Involucrin | acttatttcgggtccgctaggt | gagacatgtagagggacagagtcaag | 1.93 |
|
| Hornerin | tacaaggcgtcatcactgtcatc | atctggatcgtttggattcttcag | 2.12 |
|
| Late cornified envelope 1 A | tgcaagagtggctgagatgc | agacaacacagttggtgtcagg | 2.18 |
|
| Keratin 1 | gatgaaatcaacaagcggacaa | tggtagagtgctgtaaggaaatcaatt | 2.24 |
|
| Keratin 5 | atctctgagatgaaccggatgatc | cagattggcgcactgtttctt | 2.26 |
|
| Keratin 14 | ggcctgctgagatcaaagactac | cactgtggctgtgagaatcttgtt | 1.93 |
|
| Keratin 16 | gatcattgcggccaccat | tgctcatacttggtcctgaagtca | 2.01 |
|
| Transglutaminase 1 | cccccgcaatgagatctaca | atcctcatggtccacgtacaca | 1.99 |
|
| Transglutaminase 3 | ggaaggactctgccacaatgtc | tgtctgacttcaggtacttctcatactg | 2.06 |
|
| Cystatin M/E | tccgagacacgcacatcatc | ccatctccatcgtcaggaagtac | 1.98 |
|
| Carbonic anhydrase II | aacaatggtcatgctttcaacg | tgtccatcaagtgaaccccag | 2.02 |
|
| C-C motif chemokine ligand 26 | tcattcagtaaagaggcgaagtattatc | cagttttttggagggcatctg | 1.89 |
|
| Human beta defensin 2 | gatgcctcttccaggtgttttt | ggatgacatatggctccactctt | 1.99 |
|
| Skin-derived antileukoprotease | catgagggccagcagctt | tttaacaggaactcccgtgaca | 2.02 |
|
| Cytochrome p450 family 1A1 | ctggagaccttccgacactctt | gtaaaagcctttcaaacttgtgtctct | 2.02 |
|
| Cytochrome p450 family 1B1 | tggctgctcctcctcttcac | ccacgacctgatccaattctg | 2.02 |
|
| TCDD inducible polymerase | aagctcctccacctcttgaa | tctgcagaaacagggacttg | 2.05 |
|
| Aryl hydrocarbon receptor repressor | aaggctgctgttggagtctcttaat | gatgtagtcataaatgttctggtgcat | 2.15 |
|
| Ribosomal protein P0 | caccattgaaatcctgagtgatgt | tgaccagcccaaaggagaag | 2.02 |
*E is efficiency as fold increase in fluorescence per PCR cycle.
Antibodies used for immunohistochemistry.
| Antibody; clone | Manufacturer | Dilution |
|---|---|---|
| FLG; clone 15C10 | Leica Biosystems, Newcastle, UK | 1:100 |
| LOR; Covance 145P-100 | Covance Inc., Princeton, USA | 1:4000 |
| IVL; Mon150 | Van Duijnhoven | 1:20 |
| Ki67; MIB-1 | DAKO, Heverlee, Belgium | 1:50 |
| pAb to beta 2 defensin | Abcam, Cambridge, UK | 1:100 |
| SKALP/Elafin; 92-1 | Schalkwijk | 1:500 |